DexCom (DXCM)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$1.69 (+2.16%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of DexCom (DXCM)
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Key Insights

Critical company metrics and information

  • Share Price

    $80.06

  • Market Cap

    $31.27 Billion

  • Total Outstanding Shares

    390.60 Million Shares

  • Total Employees

    9,600

  • Dividend

    No dividend

  • IPO Date

    April 14, 2005

  • SIC Description

    Surgical & Medical Instruments & Apparatus

  • Homepage

    https://www.dexcom.com

Historical Stock Splits

If you bought 1 share of DXCM before June 13, 2022, you'd have 4 shares today.
Execution DateSplit Amount
June 13, 20224-for-1

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities$-1.37 Billion
Net Cash Flow From Operating Activities$821.70 Million
Net Cash Flow From Operating Activities, Continuing$821.70 Million
Net Cash Flow From Investing Activities$511.10 Million
Net Cash Flow From Financing Activities, Continuing$-1.37 Billion
Net Cash Flow$-22.40 Million
Net Cash Flow, Continuing$-32.30 Million
Net Cash Flow From Investing Activities, Continuing$511.10 Million
Exchange Gains/Losses$9.90 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Benefits Costs and Expenses$3.21 Billion
Diluted Average Shares$824.30 Million
Costs And Expenses$3.21 Billion
Income/Loss From Continuing Operations Before Tax$743.90 Million
Net Income/Loss Available To Common Stockholders, Basic$680.80 Million
Preferred Stock Dividends And Other Adjustments$0.00
Operating Expenses$1.81 Billion
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Income Tax Expense/Benefit, Deferred$13.40 Million
Operating Income/Loss$628.00 Million
Net Income/Loss$680.80 Million
Income/Loss From Continuing Operations After Tax$680.80 Million
Net Income/Loss Attributable To Parent$680.80 Million
Basic Average Shares$788.30 Million
Gross Profit$2.44 Billion
Selling, General, and Administrative Expenses$1.26 Billion
Income Tax Expense/Benefit$63.10 Million
Research and Development$549.00 Million
Cost Of Revenue$1.51 Billion
Revenues$3.95 Billion
Basic Earnings Per Share$1.73
Diluted Earnings Per Share$1.66
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Prepaid Expenses$62.50 Million
Current Assets$4.26 Billion
Noncurrent Assets$2.09 Billion
Other Non-current Assets$1.98 Billion
Other Current Assets$3.61 Billion
Liabilities$4.37 Billion
Inventory$586.30 Million
Assets$6.35 Billion
Intangible Assets$106.20 Million
Noncurrent Liabilities$2.64 Billion
Wages$105.80 Million
Equity$1.98 Billion
Equity Attributable To Noncontrolling Interest$0.00
Other Current Liabilities$1.63 Billion
Equity Attributable To Parent$1.98 Billion
Liabilities And Equity$6.35 Billion
Current Liabilities$1.73 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Related Companies

View additional S&P 500 companies similar to DexCom (DXCM)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.